Domestic formulation sales increased by 13.8 per cent to Rs 4,300.4 crore Y-o-Y, representing 32 per cent of the company's ...

Sequentially, revenue from operations grew by 2.9 per cent, whereas profit after tax (PAT) fell by 4.5 per cent ...

A.forall announced through its U.S. subsidiary, Milla Pharmaceuticals Inc., that it has received Abbreviated New Drug Application (ANDA) approval by the U.S. Food and Drug Administration (FDA) for a ...

Granules India's subsidiary, GPI, receives USFDA approval for Lisdexamfetamine Dimesylate Capsules, expanding ADHD treatment ...

Granules India receives FDA approval for generic ADHD drug, expanding portfolio and reinforcing presence in treatment space.

Natco Pharma receives FDA approval for Everolimus tablets, launching generic version of Afinitor Disperz in U.S. market.

Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and ...

Granules strengthens ADHD portfolio with US FDA approval for lisdexamfetamine dimesylate capsules: Our Bureau, Bengaluru Thursday, January 30, 2025, 16:15 Hrs [IST] Granules India ...

Granules India receives USFDA approval for its generic Lisdexamfetamine Dimesylate capsules, indicated for the treatment of ...

Hyderabad: Granules India Limited, a vertically integrated Indian pharmaceutical company, has announced that its wholly-owned ...

Pharmaceuticals firm, Granules India Ltd on Thursday said its arm has received a final nod from the US health regulator for its generic version of ...

Natco Pharma has received US FDA approval for its generic version of Everolimus tablets for oral suspension, indicated for ...